Newsroom

Alzheimer's Matters Blog

The Year in Review: ADDF’s Top 5 Science & Research 2019 Highlights

ADDF Impact

The Year in Review: ADDF’s Top 5 Science & Research 2019 Highlights

Over the past year, we have had many reasons to be proud of the promising work supported by the ADDF. The following is a summary of what I see as the ADDF’s most important science and research involvements of 2019. As we close out the decade, I am encouraged that we are moving closer to viable therapies and prevention strategies for Alzheimer’s disease.

Pamela J. Newman honored ADDF Hope on the Horizon Luncheon 2019

Supporter Stories

Pamela Newman: An Alzheimer’s Journey, From Frustration to Revelation to Hope

By any definition, Pamela J. Newman, Ph.D. and her late husband Henry (Hank) Kates were a power couple. But when Alzheimer’s struck Hank, suddenly the Newman-Kates family felt powerless. Together, they valiantly fought the disease until Hank’s death in 2016 at age 77. For years, Dr. Newman has been an ardent supporter of Alzheimer’s research and ADDF, serving on the Board of Overseers since 2013. In recognition of her dedication, we recently honored Pamela with the Charles Evans Award at the Tenth Annual “Hope on the Horizon” Fall Symposium & Luncheon in New York City.

ADDF-Amlyx-blog-brain-cells

Developing Drugs

Stepping Forward in Alzheimer’s Disease Research: A Combination Therapy Approach

Chief Medical Officer at Amylyx Pharmaceuticals gives a closer look at how far they have come in their recently expanded phase 2 clinical trial, supported in part by the ADDF, which is studying a combination approach to treating people with Alzheimer’s disease.

Resources

Featured Video

On April 9, the ADDF celebrated its second annual Memories Matter benefit event at Chelsea Piers, which welcome nearly 600 guests and raised over $1 million for Alzheimer's research.

View more on our YouTube channel

Fact Sheets & Publications